New study seeks clues to kidney disease in young adults

NCT ID NCT04344769

Recruiting now Knowledge-focused Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to understand how oxidative stress and the body's antioxidant defenses work in early stages of autosomal dominant polycystic kidney disease (ADPKD). Researchers will measure various biomarkers in blood and urine, and use MRI to measure kidney size. The goal is to find early signs of kidney damage that could help guide future treatments. The study involves 40 participants aged 18-30 with ADPKD and good kidney function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could identify early markers of kidney damage in ADPKD, helping future research into treatments.
What could go wrong: This is an observational study with no treatment being tested. It is small (40 people) and may not lead to immediate clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autosomal dominant polycystic kidney disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE

Contacts and locations

Locations

Mayo Clinic in Rochester
RECRUITING

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.